Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
R Pradhan, S Lu, H Yin, HY Oriana… - BMJ (Clinical …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
R Pradhan, S Lu, H Yin, O Yu, P Ernst… - … (Clinical Research ed …, 2022 - europepmc.org
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
R Pradhan, S Lu, H Yin, HY Oriana… - BMJ: British Medical …, 2022 - search.proquest.com
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
[HTML][HTML] Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population …
R Pradhan, S Lu, H Yin, HY Oriana, P Ernst, S Suissa… - The BMJ, 2022 - ncbi.nlm.nih.gov
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
[HTML][HTML] Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population …
R Pradhan, S Lu, H Yin, HY Oriana, P Ernst, S Suissa… - BMJ, 2022 - bmj.com
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
[PDF][PDF] Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
R Pradhan, S Lu, H Yin, OHY Yu, P Ernst, S Suissa… - bmj, 2022 - scholar.archive.org
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based …
R Pradhan, S Lu, H Yin, OHY Yu, P Ernst… - … (Clinical Research ed …, 2022 - europepmc.org
Objective To determine whether the use of glucagon-like peptide 1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 …